

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bengt-Ake Bengtsson
App. No.: 10/595,076
Conf. No.: 2186
Filing Date: July 29, 2003

Title: USE OF HUMAN GROWTH HORMONE IN
MULTIPLE SYSTEM ATROPHY
Art Unit: Not Yet Assigned
Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 AND 1.98**

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Forms PTO/SB/08A and PTO/SB/08B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement does not include copies of cited U.S. patents and U.S. patent publications pursuant to 37 C.F.R. 1.98(a)(2).

This Information Disclosure Statement is being filed prior to the receipt of a first Office Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b)(3).


No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey Simon Arnold & White, LLP Deposit Account 08-3038.

Respectfully submitted,

HOWREY LLP

Dated: November 7, 2006

By:

A handwritten signature in dark ink, appearing to read 'D. W. Clough', is written over the printed name.

David W. Clough, Ph.D.
Registration No.: 36,107
Customer No.: 22930

HOWREY LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60610
(312) 595-1239 (main)
(312) 595-1408 (direct)
(312) 595-2250 (fax)

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/595,076 |
| Filing Date | July 29, 2003 |
| First Named Inventor | Bengt-Ake Bengtsson |
| Art Unit | 1646 |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | 05558.0036.PCUS00 |

Sheet 1 of 3

U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | A1 | Re 33,653 | 07/30/1991 | Mark, et al. | |
| | A2 | 4,588,585 | 05/13/1986 | Mark, et al. | |
| | A3 | 4,737,462 | 04/12/1988 | Mark, et al. | |
| | A4 | 4,904,584 | 02/27/1990 | Shaw | |
| | A5 | 4,959,314 | 09/25/1990 | Mark, et al. | |
| | A6 | 4,965,195 | 10/23/1990 | Namen, et al. | |
| | A7 | 5,017,691 | 05/21/1991 | Lee, et al. | |
| | A8 | 5,116,943 | 05/26/1992 | Koths, et al. | |
| | A9 | 5,137,872 | 08/11/1992 | Seely, et al. | |
| | A10 | 5,534,617 | 07/09/1996 | Cunningham, et al. | |
| | A11 | 5,597,709 | 01/28/1997 | Rosen, et al. | |
| | A12 | 5,612,470 | 03/18/1997 | Thorner, et al. | |
| | A13 | 5,633,352 | 05/27/1997 | Dalboge, et al. | |
| | A14 | 5,635,604 | 06/03/1997 | Dalboge, et al. | |
| | A15 | 5,654,010 | 08/05/1997 | Johnson, et al. | |
| | A16 | 5,688,666 | 11/18/1997 | Bass, et al. | |
| | A17 | 5,696,089 | 12/09/1997 | Felix, et al. | |
| | A18 | 5,721,250 | 02/24/1998 | Morriello, et al. | |
| | A19 | 5,721,251 | 02/24/1998 | Chen, et al. | |
| | A20 | 5,723,616 | 03/03/1998 | Houghton, et al. | |
| | A21 | 5,726,307 | 03/10/1998 | Schoen, et al. | |
| | A22 | 5,726,319 | 03/10/1998 | Lin, et al. | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

| | | | | | | | | | | | | | | | |
|--|---------------------|---|---|--------------------|------------|-------------|---------------|----------------------|---------------------|----------|------|---------------|------------------|------------------------|-------------------|
| Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p> | | <h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/595,076</td> </tr> <tr> <td>Filing Date</td> <td>July 29, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Bengt-Ake Bengtsson</td> </tr> <tr> <td>Art Unit</td> <td>1646</td> </tr> <tr> <td>Examiner Name</td> <td>Not yet assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>05558.0036.PCUS00</td> </tr> </table> | | Application Number | 10/595,076 | Filing Date | July 29, 2003 | First Named Inventor | Bengt-Ake Bengtsson | Art Unit | 1646 | Examiner Name | Not yet assigned | Attorney Docket Number | 05558.0036.PCUS00 |
| Application Number | 10/595,076 | | | | | | | | | | | | | | |
| Filing Date | July 29, 2003 | | | | | | | | | | | | | | |
| First Named Inventor | Bengt-Ake Bengtsson | | | | | | | | | | | | | | |
| Art Unit | 1646 | | | | | | | | | | | | | | |
| Examiner Name | Not yet assigned | | | | | | | | | | | | | | |
| Attorney Docket Number | 05558.0036.PCUS00 | | | | | | | | | | | | | | |
| Sheet | 2 | of | 3 | | | | | | | | | | | | |

| U. S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A23 | 5,731,317 | 03/24/1998 | Lu, et al. | |
| | A24 | 5,736,515 | 04/07/1998 | Bengtsson, et al. | |
| | A25 | 5,767,085 | 06/16/1998 | Johansen, et al. | |
| | A26 | 5,767,118 | 06/16/1998 | Nargund, et al. | |
| | A27 | 5,767,124 | 06/16/1998 | Draper, et al. | |
| | A28 | 5,773,441 | 06/30/1998 | Hipskind, et al. | |
| | A29 | 5,776,901 | 07/07/1998 | Bowers, et al. | |
| | A30 | 5,777,112 | 07/07/1998 | Nargund, et al. | |
| | A31 | 5,792,747 | 08/11/1998 | Schally, et al. | |
| | A32 | 5,795,957 | 08/18/1998 | Deghenghi | |
| | A33 | 5,798,337 | 08/25/1998 | Somers, et al. | |
| | A34 | 5,804,578 | 09/08/1998 | Chakravarty, et al. | |
| | A35 | 5,807,985 | 09/15/1998 | Deghenghi | |
| | A36 | 5,830,433 | 11/03/1998 | Dean, et al. | |
| | A37 | 5,834,598 | 11/10/1998 | Lowman, et al. | |
| | A38 | 5,843,453 | 12/01/1998 | Holder, et al. | |
| | A39 | 5,846,936 | 12/08/1998 | Felix, et al. | |
| | A40 | 5,847,066 | 12/08/1998 | Coy, et al. | |
| | A41 | 5,849,535 | 12/15/1998 | Cunningham, et al. | |
| | A42 | 5,849,700 | 12/15/1998 | Sorensen, et al. | |
| | A43 | 5,849,704 | 12/15/1998 | Sorensen, et al. | |
| | A44 | 5,851,992 | 12/22/1998 | Sorensen | |
| | A45 | 5,869,452 | 02/09/1999 | Ng, et al. | |
| | A46 | 6,143,523 | 11/07/2000 | Cunningham, et al. | |
| | A47 | 6,335,319 | 01/01/2002 | Ng, et al. | |

| | | |
|--------------------|-----------------|--|
| Examiner Signature | Date Considered | |
|--------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

| | | | |
|--|---|--------------------------|---------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10-595,076 |
| | | Filing Date | July 29, 2003 |
| | | First Named Inventor | Bengt-Ake Bengtsson |
| | | Art Unit | 1646 |
| | | Examiner Name | Not yet assigned |
| | | Attorney Docket Number | 05558.0036.PCUS00 |
| Sheet | 3 | of | 3 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ "Number" ⁴ "Kind Code" ⁵ (if known) | | | | |
| | B1 | WO 00/42175 | 07/20/2000 | Bolder Biotechnology Inc. | | |
| | B2 | WO 02/17951 | 03/07/2002 | Colorado State University Research Foundation | | |
| | B3 | WO 02/28437 | 04/11/2002 | Ares Trading S.A. | | |
| | B4 | WO 91/09955 | 07/11/1991 | Applied Research Systems, ARS Holding MV | | |
| | B5 | WO 97/21449 | 06/19/1997 | Colorado State University Research Foundation | | |
| | B6 | WO 99/12969 | 03/18/1999 | Metabolic Pharmaceuticals Ltd. | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Examiner Signature | | | | Date Considered | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|-------------------|----|---|-----------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,076 |
| | | | | Filing Date | July 29, 2003 |
| | | | | First Named Inventor | Bengt-Ake Bengtsson |
| | | | | Group Art Unit | 1646 |
| Examiner Name | Not yet assigned | | | | |
| Attorney Docket Number | 05558.0036.PCUS00 | | | | |
| Sheet | 1 | of | 8 | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|----------------------------------|--|----------------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T² |
| | C1 | Aberg, N. David, et al., "Growth Hormone Increases Connexin-43 Expression in the Cerebral Cortex and Hypothalamus*," Endocrinology, Vol. 141, No. 10, pp. 3879-3886 (2000) | |
| | C2 | Adelman, J. P., et al., "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," DNA (N.Y.), Vol. 2, No. 3, pp. 183-193 (1983) | |
| | C3 | Alba-Roth, J., et al., "Arginine Stimulates Growth Hormone Secretion by Suppressing Endogenous Somatostatin Secretion," Journal of Clinical Endocrinology and Metabolism, Vol. 67, No. 6, pp. 1186-1189 (1988) | |
| | C4 | Albertsson-Wikland, K., et al., "Daily Subcutaneous Administration of Human Growth Hormone in Growth Hormone Deficient Children," Acta Paediatr Scand, Vol. 75, pp.89-97 (1986) | |
| | C5 | Altschul, S. F., et al., "Basic Local Alignment Search Tool," J. Mol. Biol., Vol. 215, pp. 403-410 (1990) | |
| | C6 | Altschul, S. F., et al., "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs," Nucleic Acids Research, Vol. 25, No. 17, pp. 3389-3402 (1997) | |
| | C7 | Andersson, K., et al., "Rat Growth Hormone and Hypothalamic Catecholamine Nerve Terminal Systems, Evidence for Rapid and Discrete Reductions in Dopamine and Noradrenaline Levels and Turnover in the Median Eminence of the Hypophysectomized Male Rat," European Journal of Pharmacology, Vol. 95 pp. 271-275 (1983) | |
| | C8 | Bandmann, O., et al., "Multiple-System Atrophy is Genetically Distinct from Identified Inherited Causes of Spinocerebellar Degeneration," Neurology, Vol. 49, pp. 1598-1604 (1997) | |
| | C9 | Becker, G. W., et al., "Isolation and Characterization of a Sulfoxide and a Desamido Derivative of Biosynthetic Human Growth Hormone," Biotechnology and Applied Biochemistry, Vol. 10, pp. 326-337 (1988) | |

| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|-------------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,076 |
| | | | | Filing Date | July 29, 2003 |
| | | | | First Named Inventor | Bengt-Ake Bengtsson |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Not yet assigned |
| Sheet | 2 | of | 8 | Attorney Docket Number | 05558.0036.PCUS00 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
| | C10 | Bewley, T. A., et al., "Sequence Comparison of Human Pituitary Growth Hormone, Human Chorionic Somatomammotropin, and Ovine Pituitary Growth and Lactogenic Hormones," Int. J. Peptide Protein Res., Vol. 4, pp. 281-287 (1972) | |
| | C11 | Bowers, C. Y., et al., "On the Actions of the Growth Hormone-Releasing Hexapeptide, GHRP*," Endocrinology, Vol. 128, No. 4, pp. 2027-2035 (1991) | |
| | C12 | Burman, P., et al., "Quality of Life in Adults with Growth Hormone (GH) Deficiency: Response to Treatment with Recombinant Human GH in a Placebo-Controlled 21-Month Trial," Journal of Clinical Endocrinology and Metabolism, Vol. 80, No. 12, pp. 3585-3590 (1995) | |
| | C13 | Camanni, F., et al., "Growth Hormone-Releasing Peptides and Their Analogs," Frontiers in Neuroendocrinology, Vol. 19, pp. 47-72 (1998) | |
| | C14 | Chen, E. Y., et al., "The Human Growth Hormone Locus: Nucleotide Sequence, Biology, and Evolution," Genomics, Vol. 4, pp. 479-497 (1989) | |
| | C15 | Daniel, S. E., "The Neuropathology and Neurochemistry of Multiple System Atrophy," Mathias CJ, Bannister R eds. Autonomic Failure: A Textbook of The Autonomic Nervous System, 4 th ed., Oxford University Press, pp. 321-328 (1999) | |
| | C16 | DeNoto, F., et al., "Human Growth Hormone DNA Sequence and mRNA Structure: Possible Alternative Splicing," Nucleic Acids Research, Vol. 9, No. 15, pp. 3719-3730 (1981) | |
| | C17 | Devereux, J., et al., "A Comprehensive Set of Sequence Analysis Programs for the VAX," Nucleic Acids Research, Vol. 12, No. 1, pp. 387-395 (1984) | |
| | C18 | Eecken, H. V., et al., "Striopallidal-Nigral Degeneration, An Hitherto Undescribed Lesion in Paralysis Agitans," American Association of Neuropathologists, Vol. 19, pp. 159-161 (1960) | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DM_US8398278.v3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|-------------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,076 |
| | | | | Filing Date | July 29, 2003 |
| | | | | First Named Inventor | Bengt-Ake Bengtsson |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Not yet assigned |
| Sheet | 3 | of | 8 | Attorney Docket Number | 05558.0036.PCUS00 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
| | C19 | Felix, A. M., et al., "Pegylated Peptides IV Enhanced Biological Activity of Site-Directed Pegylated GRF Analogs," Int. J. Peptide Protein Res., Vol. 46, pp. 253-264 (1995) | |
| | C20 | Friend, K., et al., "Pyridostigmine Treatment Selectively Amplifies the Mass of GH Secreted per Burst Without Altering GH Burst Frequency, Half-Life, Basal GH Secretion or the Orderliness of GH Release," European Journal of Endocrinology, Vol. 137, pp. 377-386 (1997) | |
| | C21 | Gertler, A., et al., "Inhibition of Lactogenic Activities of Ovine Prolactin and Human Growth Hormone (hGH) by a Novel Form of a Modified Recombinant hGH*," Endocrinology, Vol. 118, No. 2, pp. 720-726 (1985) | |
| | C22 | Ghigo, E., et al., "Orally Active Growth Hormone Secretagogues: State of the Art and Clinical Perspectives," Annals of Medicine Vol. 30, pp. 159-168 (1998) | |
| | C23 | Gilman, S., et al., "Consensus Statement on the Diagnosis of Multiple System Atrophy," Journal of the Autonomic Nervous System, Vol. 74, pp. 189-192 (1998) | |
| | C24 | Goeddel, D. V., et al., "Direct Expression in <i>Escherichia coli</i> of a DNA Sequence Coding for Human Growth Hormone," Nature, Vol. 281, pp. 544-548 (1979) | |
| | C25 | Graft, L., et al., "Human Somatotropin," The Journal of Biological Chemistry, Vol. 257, No. 5, pp. 2365-2369 (1982) | |
| | C26 | Grantham, R., "Amino Acid Difference Formula to Help Explain Protein Evolution," Science, Vol. 185, pp. 862-864 (1974) | |
| | C27 | Harvey, S., et al., "Growth Hormone: Neurocrine and Neuroendocrine Perspectives," Growth Regulation, Vol. 3, pp. 161-171 (1993) | |

| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|-------------------|----|---|-----------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,076 |
| | | | | Filing Date | July 29, 2003 |
| | | | | First Named Inventor | Bengt-Ake Bengtsson |
| | | | | Group Art Unit | 1646 |
| Examiner Name | Not yet assigned | | | | |
| Attorney Docket Number | 05558.0036.PCUS00 | | | | |
| Sheet | 4 | of | 8 | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
| | C28 | Holmberg, B., et al., "Increased Cerebrospinal Fluid Levels of Neurofilament Protein in Progressive Supranuclear Palsy and Multiple-System Atrophy Compared with Parkinson's Disease," Movement Disorders, Vol. 13, No. 1, pp. 70-77 (1998) | |
| | C29 | Hsiung, H. M., et al., "Use of Bacteriocin Release Protein in <i>E. Coli</i> For Excretion of Human Growth Hormone into the Culture Medium," Biotechnology, Vol. 7, pp. 267-271 (1989) | |
| | C30 | Hughes, A. J., et al., "Apomorphine Test to Predict Dopaminergic Responsiveness in Parkinsonian Syndromes," The Lancet, Vol. 336, pp. 32-34 (1990) | |
| | C31 | Hughes, A. J., et al., "Challenge Tests to Predict the Dopaminergic Response in Untreated Parkinson's Disease," Neurology, Vol. 41, pp. 1723-1725 (1991) | |
| | C32 | Hughes, A. J., et al., "The Dopaminergic Response in Multiple System Atrophy," Journal Of Neurology, Neurosurgery, and Psychiatry, Vol. 55, pp. 1009-1013 (1992) | |
| | C33 | Johansson, J-O., et al., "Growth Hormone and Psychosocial and Central Nervous Effects," Growth Hormone in Adults-Physiological and Clinical Aspects, 2 nd edition, Cambridge University Press, pp. 349-372 (2000) | |
| | C34 | Jorgensen, K. D., et al., "Pharmacokinetics of Biosynthetic and Pituitary Human Growth Hormones in Rats," Pharmacology & Toxicology, Vol. 63, pp. 129-134 (1988) | |
| | C35 | Kimber, J. R., et al., "Distinction of Idiopathic Parkinson's Disease from Multiple-System Atrophy by Stimulation of Growth-Hormone Release with Clonidine," The Lancet, Vol. 349, pp. 1877-1881 (1997) | |
| | C36 | Kimber, J., et al., "Physiological, Pharmacological and Neurohormonal Assessment of Autonomic Function in Progressive Supranuclear Palsy," Brain, Vol. 123, pp. 1422-1430 (2000) | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|-------------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,076 |
| | | | | Filing Date | July 29, 2003 |
| | | | | First Named Inventor | Bengt-Ake Bengtsson |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Not yet assigned |
| Sheet | 5 | of | 8 | Attorney Docket Number | 05558.0036.PCUS00 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
| | C37 | Klein, C., et al., "The 'Cold Hands Sign' in Multiple System Atrophy," Movement Disorders, Vol. 12, No. 4, pp. 514-518 (1997) | |
| | C38 | Kraft, E., et al., "The Combination of Hypointense and Hyperintense Signal Changes on T ₂ -Weighted Magnetic Resonance Imaging Sequences," Archives of Neurology, Vol. 56, pp. 225-228 (1999) | |
| | C39 | Lewis, et al., "Hyperglycemic Activity of Growth Hormone," Endocrinology, Vol. 101, No. 5, pp. 1588-1603 (1977) | |
| | C40 | Lewis, U. J., et al., "A Naturally Occurring Structural Variant of Human Growth Hormone*," The Journal of Biological Chemistry, Vol. 253, No. 8, pp. 2679-2687 (1978) | |
| | C41 | Lewis, U. J., et al., "Altered Proteolytic Cleavage of Human Growth Hormone as a Result of Deamidation*," The Journal of Biological Chemistry, Vol. 256, No. 22 pp. 11645-11650 (1981) | |
| | C42 | Lewis, U. J., et al., "Human Growth Hormone: Additional Members of the Complex," Endocrinology, Vol. 104, No. 5, pp. 1256-1265 (1979) | |
| | C43 | Lewis, U. J., et al., "The 20,000-Dalton Variant of Human Growth Hormone: Location of the Amino Acid Deletions," Biochemical and Biophysical Research Communications, Vol. 92, No. 2, pp. 511-516 (1980) | |
| | C44 | Litvan, I., et al., "Clinical Research Criteria for the Diagnosis of Progressive Supranuclear Palsy (Steel-Richardson-Olszewski Syndrome): Report of the NINDS-SPSP International Workshop," Neurology, Vol. 47, pp. 1-9 (1996) | |
| | C45 | Litvan, I., et al., "What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?" Archives of Neurology, Vol. 54, pp. 937-944 (1997) | |
| | C46 | Martial, J. A., et al., "Human Growth Hormone: Complementary DNA Cloning and Expression in Bacteria," Science, Vol. 205, pp. 602-607 (1979) | |
| | C47 | Meinkoth, J., et al., "Hybridization of Nucleic Acids Immobilized on Solid Supports," Analytical Biochemistry, Vol. 138, pp. 267-284 (1984) | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|-------------------|----|---|-----------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,076 |
| | | | | Filing Date | July 29, 2003 |
| | | | | First Named Inventor | Bengt-Ake Bengtsson |
| | | | | Group Art Unit | 1646 |
| Examiner Name | Not yet assigned | | | | |
| Attorney Docket Number | 05558.0036.PCUS00 | | | | |
| Sheet | 6 | of | 8 | | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|----------------|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² | |
| | C48 | Moore, J. A., et al., "Equivalent Potency and Pharmacokinetics of Recombinant Human Growth Hormones With or Without an N-Terminal Methionine," Endocrinology, Vol. 122, No. 6, pp. 2920-2926 (1988) | | |
| | C49 | Pearson, W. R., "Rapid and Sensitive Sequence Comparison with FASTP and FASTA," Methods in Enzymology, Vol. 183, pp. 63-99 (1990) | | |
| | C50 | Pearson, W. R., et al., "Improved Tools for Biological Sequence Comparison," Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 2444-2448 (1988) | | |
| | C51 | Polo, K. B., et al., "Botulinum Toxin-A Improves the Rigidity of Progressive Supranuclear Palsy," Annals of Neurology, Vol. 35, pp. 237-239 (1994) | | |
| | C52 | Quinn, N, "Multiple System Atrophy—The Nature of The Beast," Journal of Neurology, Neurosurgery, and Psychiatry. Special Supplement, pp.78-89 (1989) | | |
| | C53 | Raizada, M. K., et al., "The Role of Insulin-Like Growth Factors in the Nervous System," Annals of the New York Academy of Sciences, Vol. 692, pp. 10-21 (1993) | | |
| | C54 | Rosengren, L. E., et al., "A Sensitive ELISA for Glial Fibrillary Acidic Protein: Application in CSF of Adults," Journal of Neuroscience Methods, Vol. 51, pp. 197-204 (1994) | | |
| | C55 | Rosengren, L. E., et al., "Glial Fibrillary Acidic Protein in CSF of Multiple Sclerosis Patients: Relation to Neurological Deficit," Journal of the Neurological Sciences, Vol. 133, pp. 61-65 (1995) | "" | |
| | C56 | Rosengren, L. E., et al., "Neurofilament Protein Levels in CSF are Increased in Dementia," Neurology, Vol. 52, pp. 1090-1093 (1999) | | |
| | C57 | Rosengren, L. E., et al., "Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF," Journal of Neurochemistry, Vol. 67, pp. 2013-2018 (1996) | | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|-------------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,076 |
| | | | | Filing Date | July 29, 2003 |
| | | | | First Named Inventor | Bengt-Ake Bengtsson |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Not yet assigned |
| Sheet | 7 | of | 8 | Attorney Docket Number | 05558.0036.PCUS00 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
| | C58 | Rossi, P., et al., "Acute Challenge with Apomorphine and Levodopa in Parkinsonism," European Neurology, Vol. 43, pp. 95-101 (2000) | |
| | C59 | Schrag, A., et al., "Clinical Usefulness of Magnetic Resonance Imaging in Multiple System Atrophy," Journal Of Neurology Neurosurg. Psychiatry, Vol. 65, pp. 65-71 (1998) | |
| | C60 | Singh, R. N. P., et al., "Modified Forms of Human Growth Hormone with Increased Biological Activities," Endocrinology, Vol. 94, No. 3, pp. 883-891 (1974) | |
| | C61 | Smith, R. G., et al., "A Nonpeptidyl Growth Hormone Secretagogue," Science, Vol. 260, pp. 1640-1643 (1993) | |
| | C62 | Smith, T. F., et al., "Comparison of Biosequences," Advances in Applied Mathematics, Vol. 2, pp. 482-489 (1981) | |
| | C63 | Tannenbaum, G., "Evidence for Autoregulation of Growth Hormone Secretion Via The Central Nervous System," Endocrinology, Vol. 107, No. 6, pp. 2117-2120 (1980) | |
| | C64 | Thorlacius-Ussing, O., "Zinc in the Anterior Pituitary of Rat: A Histochemical and Analytical Work," Neuroendocrinology, Vol. 45, pp. 233-242 (1987) | |
| | C65 | Thorner, M. O., et al., "Growth Hormone-Releasing Hormone and Growth Hormone-Releasing Peptide as Therapeutic Agents to Enhance Growth Hormone Secretion in Disease and Aging," Recent Progress in Hormone Research, Vol. 52, pp. 215-246 (1987) | |
| | C66 | Wenning, G. K., et al., "Minimal Change Multiple System Atrophy," Movement Disorders, Vol. 9, No. 2, pp. 161-166 (1994) | |
| | C67 | Wenning, G. K., et al., "Multiple System Atrophy: A Review of 203 Pathologically Proven Cases," Movement Disorders, Vol. 12, No. 2, pp. 133-147 (1997) | |

| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DM_US8398278.v3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|-------------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,076 |
| | | | | Filing Date | July 29, 2003 |
| | | | | First Named Inventor | Bengt-Ake Bengtsson |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Not yet assigned |
| Sheet | 8 | of | 8 | Attorney Docket Number | 05558.0036.PCUS00 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|--|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
| | C68 | Wenning, G. K., et al., "Olivopontocerebellar Pathology in Multiple System Atrophy," Movement Disorders, Vol. 11, No. 2, pp. 157-162 (1996) | |

| | | | |
|-------------------------------|--|----------------------------|--|
| Examiner Signature | | Date Considered | |
|-------------------------------|--|----------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DM_US8398278.v3